Prolactin receptor antagonist - Oncolix

Drug Profile

Prolactin receptor antagonist - Oncolix

Alternative Names: Prolanta

Latest Information Update: 05 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Oncolix
  • Class Hormones; Pituitary gonadotropins
  • Mechanism of Action Prolactin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Preclinical Breast cancer

Most Recent Events

  • 05 Dec 2017 Prolactin receptor antagonist is still in preclinical studies for Breast cancer in USA
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Breast-cancer in USA (SC)
  • 26 Apr 2016 Prolanta™ receives Orphan Drug status for Ovarian cancer in USA prior to this date
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top